D-0279-2022 Class II Terminated

Recalled by Teligent Pharma, Inc. — Buena, NJ

FDA drug recall D-0279-2022 was initiated by Teligent Pharma, Inc. on Oct 12, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent. The recall status is terminated (terminated Jun 18, 2024). Affected quantity: 7,008 glass bottles.

Recall details

Product Type
Drugs
Report Date
Dec 22, 2021
Initiation Date
Oct 12, 2021
Termination Date
Jun 18, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,008 glass bottles

Product description

Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL glass bottles, Rx Only, Manufactured by: Teligent Pharma Inc., Buena, NJ 06310, Distributed by: McKesson Corporation dba Sky Packaging, 497 Southridge Blvd, Suite 101, Memphis, TN 36141, NDC 63739-997-64.

Reason for recall

CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 16306, Exp. Date 01/2024.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0279-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0279-2022. Report a data issue: hello@regdatalab.com.